Abstract:
Process for making a cathode active material for a lithium ion battery, said process comprising the following steps: (a) synthesizing a mixed oxide according to general formula Li 1+x TM 1-x O 2 at a temperature in the range of from 750 to 1000°C in an oxidizing atmosphere, wherein TM is a combination of two or more transition metals selected from Mn, Co and Ni and, optionally, at least one more metal selected from Ba, Al, Ti, Zr, W, Fe, Cr, K, Mo, Nb, Mg, Na and V, and wherein x is in the range of from zero to 0.2, (b) cooling down the material obtained from step (a) to a temperature in the range of from 100 to 400°C, (c) adding at least one reactant selected from BF 3 , SO 2 and SO 3 at said 100 to 400°C, (d) cooling down to a temperature of 50°C or below.
Abstract:
The present invention refers to a secretion-competent mutein of the α-subunit of human Interleukin 27 and to a human heterodimeric Interleukin 27. The present invention further refers to a nucleic acid molecule comprising a nucleotide sequence encoding a secretion- competent mutein of the α-subunit of human Interleukin 27 or the human heterodimeric Interleukin 27, to a host cell containing a nucleic acid molecule comprising a nucleotide sequence encoding a secretion-competent mutein of the α-subunit of human Interleukin 27 or of the human heterodimeric Interleukin 27. The invention also refers to an immune modulator comprising a secretion-competent mutein of the α-subunit of human Interleukin 27 or of the human heterodimeric Interleukin 27, to the respective use thereof as well as to a method of producing saidsecretion-competent muteins and to a secretion-incompetent mutein of the α-subunit of mouse Interleukin 27and a secretion-competent mutein of the β-subunit of mouse Interleukin 27.
Abstract:
The invention relates to a method of determining the dissociation rate constant (k off ) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.
Abstract:
The disclosure refers to a synthesis filter bank, comprising: a transform module which is configured to receive a plurality of input signals, transform the plurality of input signals, and output a plurality of transformed signals, a plurality of filter modules, which are coupled to the transform module, and wherein each filter module of the plurality of filter modules is configured to receive two transformed signals from the transform module, process the two received transformed signals and output two processed signals, and a parallel-to-serial module which is coupled to the plurality of filter modules and which is configured to receive the processed signals from the plurality of filter modules, combine the received processed signals and output a combined signal. Furthermore, an analysis filter bank, a filter bank and methods for operating a synthesis filter bank and for operating an analysis filter bank are disclosed.
Abstract:
The present invention relates to a method for providing a neopeptide-specific T cell, wherein the neopeptide-specific T cell forms a complex having a half-life (T 1/2 ) of at least 50 s with a neopeptide-MHC monomer. The present invention further relates to a T cell obtainable by the method as well as a pharmaceutical composition comprising such T cells.
Abstract:
The present invention relates to methods and pharmaceutical compositions for the treatment of allergic contact dermatitis (ACD). In particular, the present invention relates to a method for the treatment of allergic contact dermatitis (ACD) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one RIG-I-like receptor ligand.
Abstract:
The present invention is directed to a method of forming multilayer silk protein films and a multilayer film obtained therefrom. The invention is further directed to various materials, products and compositions containing said multilayer film and to the use of Said multilayer film in several applications.
Abstract:
The present invention is directed to a method of modifying a spider silk protein and a spider silk protein obtainable by said method. The invention further pertains to a nucleic acid sequence coding for a modified spider silk protein, a vector containing said sequences and host cells transformed with this vector. The invention furthermore is directed to a pharmaceutical or cosmetical composition containing a modified spider silk protein as defined herein and the use of said modified sequences in various fields, in particular in the fields of medicine, cosmetics and technical applications.
Abstract:
The present invention is directed to recombinant spider silk proteins, nucleic acids, coding for these recombinant spider silk proteins, as well as hosts suitable for expressing those nucleic acids. Furthermore, the present invention is directed to a method of aggregation of spider silk proteins and the use of the proteins in the field of biotechnology and/or medicine and other industrial fields, in particular in the manufacture of automotive parts, in the aircraft construction, in the processing of textiles and leather, as well as in the manufacture and processing of paper and the like.